MedKoo Cat#: 463499 | Name: para-NitroBlebbistatin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

para-NitroBlebbistatin is a selective cell-permeable inhibitor of non-muscle myosin II ATPases, being more stable and less phototoxic than Blebbistatin.

Chemical Structure

para-NitroBlebbistatin
para-NitroBlebbistatin
CAS#1621326-32-6

Theoretical Analysis

MedKoo Cat#: 463499

Name: para-NitroBlebbistatin

CAS#: 1621326-32-6

Chemical Formula: C18H15N3O4

Exact Mass: 337.1063

Molecular Weight: 337.34

Elemental Analysis: C, 64.09; H, 4.48; N, 12.46; O, 18.97

Price and Availability

Size Price Availability Quantity
1mg USD 450.00 2 Weeks
5mg USD 900.00 2 Weeks
10mg USD 1,425.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
para-NitroBlebbistatin; para NitroBlebbistatin; para-Nitro Blebbistatin; para-Nitro-Blebbistatin; (–)-4'-amino-Blebbistatin; p-amino-Blebbistatin; (S)-4'-amino-Blebbistatin;
IUPAC/Chemical Name
(S)-3a-hydroxy-6-methyl-1-(4-nitrophenyl)-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one
InChi Key
KAUXNLHXGQGFOS-GOSISDBHSA-N
InChi Code
InChI=1S/C18H15N3O4/c1-11-2-7-15-14(10-11)16(22)18(23)8-9-20(17(18)19-15)12-3-5-13(6-4-12)21(24)25/h2-7,10,23H,8-9H2,1H3/t18-/m1/s1
SMILES Code
O=C1[C@@]2(O)C(N(C3=CC=C([N+]([O-])=O)C=C3)CC2)=NC4=C1C=C(C)C=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
para-Nitroblebbistatin is a non-cytotoxic, photostable, fluorescent and specific Myosin II inhibitor.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMF 20.0 59.29
DMF:PBS (pH 7.2) (1:1) 0.5 1.48
DMSO 17.3 51.14
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 337.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Dvinskikh L, Sparks H, MacLeod KT, Dunsby C. High-speed 2D light-sheet fluorescence microscopy enables quantification of spatially varying calcium dynamics in ventricular cardiomyocytes. Front Physiol. 2023 Feb 14;14:1079727. doi: 10.3389/fphys.2023.1079727. PMID: 36866170; PMCID: PMC9971815. 2: Dvinskikh L, Sparks H, Brito L, MacLeod KT, Harding SE, Dunsby C. Remote- refocusing light-sheet fluorescence microscopy enables 3D imaging of electromechanical coupling of hiPSC-derived and adult cardiomyocytes in co- culture. Sci Rep. 2023 Feb 27;13(1):3342. doi: 10.1038/s41598-023-29419-w. PMID: 36849727; PMCID: PMC9970973. 3: Gollapudi SK, Ma W, Chakravarthy S, Combs AC, Sa N, Langer S, Irving TC, Nag S. Two Classes of Myosin Inhibitors, Para-nitroblebbistatin and Mavacamten, Stabilize β-Cardiac Myosin in Different Structural and Functional States. J Mol Biol. 2021 Nov 19;433(23):167295. doi: 10.1016/j.jmb.2021.167295. Epub 2021 Oct 8. PMID: 34627791; PMCID: PMC9044501. 4: Lilienberg J, Hegyi Z, Szabó E, Hathy E, Málnási-Csizmadia A, Réthelyi JM, Apáti Á, Homolya L. Pharmacological Modulation of Neurite Outgrowth in Human Neural Progenitor Cells by Inhibiting Non-muscle Myosin II. Front Cell Dev Biol. 2021 Sep 17;9:719636. doi: 10.3389/fcell.2021.719636. PMID: 34604221; PMCID: PMC8484915. 5: Gyimesi M, Rauscher AÁ, Suthar SK, Hamow KÁ, Oravecz K, Lőrincz I, Borhegyi Z, Déri MT, Kiss ÁF, Monostory K, Szabó PT, Nag S, Tomasic I, Krans J, Tierney PJ, Kovács M, Kornya L, Málnási-Csizmadia A. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2. J Pharmacol Exp Ther. 2021 Mar;376(3):358-373. doi: 10.1124/jpet.120.000167. Epub 2021 Jan 19. PMID: 33468641. 6: Tang W, Blair CA, Walton SD, Málnási-Csizmadia A, Campbell KS, Yengo CM. Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels. Front Physiol. 2017 Jan 9;7:659. doi: 10.3389/fphys.2016.00659. PMID: 28119616; PMCID: PMC5220080. 7: Várkuti BH, Képiró M, Horváth IÁ, Végner L, Ráti S, Zsigmond Á, Hegyi G, Lenkei Z, Varga M, Málnási-Csizmadia A. A highly soluble, non-phototoxic, non- fluorescent blebbistatin derivative. Sci Rep. 2016 May 31;6:26141. doi: 10.1038/srep26141. PMID: 27241904; PMCID: PMC4886532. 8: Képiró M, Várkuti BH, Végner L, Vörös G, Hegyi G, Varga M, Málnási-Csizmadia A. para-Nitroblebbistatin, the non-cytotoxic and photostable myosin II inhibitor. Angew Chem Int Ed Engl. 2014 Jul 28;53(31):8211-5. doi: 10.1002/anie.201403540. Epub 2014 Jun 20. PMID: 24954740.